Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
170 Leser
Artikel bewerten:
(0)

RayBiotech, Inc. Convenes 2012 Global Distributor Conference to Address Strategic Growth Objectives

NORCROSS, Ga., Oct. 17, 2012 /PRNewswire/ --RayBiotech, Inc. ("RBI") today announced that it is convening a two-day Global Distributor Conference at its headquarters in suburban Atlanta, Georgia. Distributors representing over thirty-five international countries will participate in this conference where RBI management will address expanded strategic growth objectives for the next five years. In addition, the conference will focus on new product launches, new service offerings and overall technical training related to the RayBiotech portfolio of high-value research products and services. Included will be recognition of those distributors who have excelled in their development of the RayBiotech business within their respective geographic territories. Simultaneous with the Atlanta-based conference, over twenty distributors from throughout China, will be meeting in Chong Qing, China, participating in a similar conference led by Ray Huang, M.D., Ph.D., Co-founder and CEO of RayBiotech, Inc.

Commenting on the Global Distributor Conference, RayBiotech's President, Chief Operating Officer and Co-founder, Ms. Rani Huang, stated, "Significant investments have been made to further enhance our growth and development over the next five years. Particularly, this includes the areas of GLP assay services, Business Development, Sales and Marketing, and especially, our focus on achieving above market-performance through our outstanding distributor network. This is why we're meeting this week, both in Atlanta and in Chong Qing, with our leading distributors to review our growth objectives and plans. We recognize that in order to achieve growth significantly above that of our markets, continuous focus on innovation, high quality products and services and, outstanding execution in customer development, will all be necessary. In addition, we're very pleased to have recently successfully validated the GMP status of the production of our products. We're honored to have such a high-performance Distributor Network and look forward to continued mutual growth and development over the next five years and beyond."

About RayBiotech, Inc.

RayBiotech (http://www.raybiotech.com) pioneered the development of antibody and protein array technologies and provides reliable high-throughput platforms for identifying disease mechanisms, screening and validation of novel biomarkers and identification of new drug targets. In 2001 RayBiotech introduced the first commercially available cytokine antibody array. Since then, RayBiotech array products have been featured in thousands of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech has established a leading reputation for the high quality and innovative developments provided to the research community. RayBiotech continues to lead in the development of protein array technologies and is focused on further meeting the needs of clients in translating new knowledge of human biology to improved health. A spin-off from Emory University's School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).

For More Information:

Rob Burgess, PhD
Director, Business Development
RayBiotech, Inc.
Phone: 770-729-2992
Email: rob@raybiotech.com

SOURCE RayBiotech, Inc.

© 2012 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.